The ongoing legal battle between Divya Pharmacy and Patanjali Ayurved Limited and the Maharashtra government has taken an interesting turn. The Bombay High Court has temporarily halted raids and confiscations of Ayurvedic products by the state's Food and Drug Administration (FDA) over allegedly misleading labels. This decision comes as a response to the Centre's assurance of a uniform nationwide position on Ayurvedic product labeling and advertising.
The case revolves around the FDA's action under the Drugs and Magic Remedies (Objectionable Advertisements) Act, which led to the seizure of products with labels claiming cures for cancer, diabetes, and other ailments. The petitioners, Divya Pharmacy and Patanjali Ayurved Limited, argue that indication labeling is an industry-wide practice in Ayurveda and should not be treated as a violation specific to Patanjali.
Senior advocate Birendra Saraf, representing the petitioners, made a compelling argument, emphasizing the unfairness of singling out Patanjali while allowing other companies to engage in similar practices. He urged the authorities to issue a general direction to all Ayurvedic manufacturers to stop indication labeling, providing them with a reasonable time to comply.
Solicitor General Tushar Mehta, representing the Centre, supported the petitioners' stance, highlighting the role of qualified doctors in prescribing Ayurvedic medicines and the potential harm caused by confiscating or taking harsh actions against these products. He suggested that a holistic view of the matter is necessary before any further actions are taken.
The state's lawyer, Chief Public Prosecutor Shishir Hiray, agreed to refrain from precipitating the issue by continuing raids, seizures, and confiscations. The court has issued a notice to the respondent authorities and sought the Centre's reply by June 25. The interim relief sought by the petitioners will be considered at the next hearing on July 2.
This case raises important questions about the regulation of Ayurvedic products and the balance between ensuring consumer protection and maintaining the marketability of legitimate businesses. The outcome will likely have significant implications for the Ayurvedic industry and the approach to labeling and advertising practices across the country.
